Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.

Lung cancer (Amsterdam, Netherlands) - 1 Nov 2020

Alborelli Ilaria, Bratic Hench Ivana, Chijioke Obinna, Prince Spasenija Savic, Bubendorf Lukas, Leuenberger Laura P, Tolnay Markus, Leonards Katharina, Quagliata Luca, Jermann Philip, Matter Matthias S

Abstract excerpt

OBJECTIVES: Tumor mutational burden (TMB) has emerged as a promising predictive biomarker for immune checkpoint inhibitor therapy. While the feasibility of TMB analysis on formalin-fixed paraffin-embedded (FFPE) samples has been thoroughly evaluated, only limited analyses have been performed on cytological samples, and no dedicated study has investigated concordance of TMB between different sample types. Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Mutation

Share to Tumor Burden

Source

Identifiers

PMID: 32980613
DOI: 10.1016/j.lungcan.2020.08.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.PMID 32980613Read ↗

Tumor mutational burden on cytological samples: A pilot study.Semantic proximity Read ↗

Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real‐life analysis of three larger gene panelsSemantic proximity Read ↗

Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.Semantic proximity Read ↗

FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.Semantic proximity Read ↗

Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small Cell Lung CancerSemantic proximity Read ↗

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.Semantic proximity Read ↗

Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer.Semantic proximity Read ↗

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB.Semantic proximity Read ↗

RNA Sequencing Data for FFPE Tumor Blocks Can Be Used for Robust Estimation of Tumor Mutation Burden in Individual BiosamplesSemantic proximity Read ↗

Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.Semantic proximity Read ↗

Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Evaluating Diff-Quik cytology smears for large-panel mutation testing in lung cancer-Predicting DNA content and success with low-malignant-cellularity samples.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.